Last week, the Federal Circuit decided Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 23-1169 (Fed. Cir. June 25, 2024), a case that spotlighted the issues of skinny labeling and induced ...
The Association for Accessible Medicines, and the Biosimilars Council, a division of AAM, submitted a formal statement for the record for the Senate Committee on the Judiciary hearing on drug pricing ...
The Supreme Court may soon address a recent, pivotal case involving the use of “skinny labels” to avoid inducing infringement in pharmaceutical patent infringement cases. The outcome could clarify ...
Participants examined the challenges and opportunities to update oncology drug labeling that is inconsistent with the current evidence base and use in clinical practice. Discussions focused on what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback